SCHLAGWORTE: Dr Sofia Ioannidou
Where to next after the Gilead-Tubulis deal?
Gilead’s acquisition of Munich-based Tubulis earlier this year has put German antibody-drug conjugate (ADC) innovation into the global spotlight. With a total deal value...